<https://www.empr.com/#website>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>
<https://www.empr.com/home/news/drugs-in-the-pipeline/risankizumab-bla-submitted-for-moderate-to-severe-plaque-psoriasis/>